Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: bio-techne.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/22/2024 | $85.00 | Buy → Neutral | Citigroup |
2/8/2024 | $80.00 | Sector Outperform | Scotiabank |
2/2/2024 | $65.00 | Buy → Hold | Stifel |
12/7/2023 | $80.00 | Buy | UBS |
8/28/2023 | Outperform | William Blair | |
1/10/2023 | $90.00 | Underweight → Equal Weight | Wells Fargo |
12/14/2022 | $100.00 | Buy | Deutsche Bank |
12/12/2022 | $81.25 → $100.00 | Neutral → Buy | Citigroup |
12/7/2022 | $89.00 | Sector Perform | RBC Capital Mkts |
8/25/2022 | $465.00 | Outperform | Credit Suisse |
PHILADELPHIA, Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex. The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant support
ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex. The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant support allowing for
ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ:TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing. The ProPakTM GMP Cytokine product consists of a weldable bag filled with liquid formulated GMP-grade cytokines, specifically interleukin-7 (IL-7) or interleukin-15 (IL-15), commonly used in the ex vivo manufacturing of CAR-T and TCR-T cells. The quantity of IL-7 and IL-15 contained in each ProPakTM is sufficient to dose a one (1) liter G-Rex bioreactor at the recommended 10ng/mL concentration. The use of ProPak GM
ST. PAUL, Minn., Aug. 27, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant. Dr. Feldman's $300,000 G-Rex Grant will enable expeditious development of Stanford Medicine's LCGM's G-Rex platform for CAR-T cell therapy manufacturing, which will be offered to internal investigators and external developers who are seeking its development and manufacturing services. "Stanford's LCGM anticipates a need to support a greater number
MINNEAPOLIS, Aug. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare ConferenceSeptember 4, 20244:05 PM EDT 2024 Wells Fargo Healthcare ConferenceSeptember 6, 202411:00 AM EDT Baird 2024 Global Healthcare ConferenceSeptember 10, 20241:25 PM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-TechneBio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovat
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. Full year organic revenue increased 1% (2% reported) to $1.2 billion.GAAP earnings per share (EPS) was $0.25 versus $0.47 one year ago. Delivered adjusted EPS of $0.49 compared to $0.55 one year ago. Full year GAAP EPS was $1.05 versus $1.76 one year ago. Full year adjusted EPS was $1.77 versus $1.99 one year ago.Strong commercial execution in Diagnostics & Genomics led to 9% organic segment growth (15% reported) in the fo
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific d
MINNEAPOLIS, July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems. This state-of-the-art instrument enables simultaneous processing of up to 100 samples in a single 3-hour run, allowing scientists to process more samples in a day. Leo also provides 4-times the experimental size of Jess or Abby to facilitate quantitative assay designs including standard curves, QC samples, blanks, duplicates and reference standards. Leo's enhanced quantitative capabilities empower custom
MINNEAPOLIS, July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. Bio-Techne joined Foresite Capital, and other investors, in this funding round. Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is an innovative leader in the development, and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. Spear Bio's proprietary Successive Proximity Extension
MINNEAPOLIS, July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT to review fourth quarter and fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 7, 2024 Dial-in: 1-800-343-4136 or 1-203-518-9843 (for international callers) Conference ID: BioTechne Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
Citigroup downgraded Bio-Techne from Buy to Neutral and set a new price target of $85.00
Scotiabank initiated coverage of Bio-Techne with a rating of Sector Outperform and set a new price target of $80.00
Stifel downgraded Bio-Techne from Buy to Hold and set a new price target of $65.00
UBS initiated coverage of Bio-Techne with a rating of Buy and set a new price target of $80.00
William Blair initiated coverage of Bio-Techne with a rating of Outperform
Wells Fargo upgraded Bio-Techne from Underweight to Equal Weight and set a new price target of $90.00
Deutsche Bank initiated coverage of Bio-Techne with a rating of Buy and set a new price target of $100.00
Citigroup upgraded Bio-Techne from Neutral to Buy and set a new price target of $100.00 from $81.25 previously
RBC Capital Mkts initiated coverage of Bio-Techne with a rating of Sector Perform and set a new price target of $89.00
Credit Suisse initiated coverage of Bio-Techne with a rating of Outperform and set a new price target of $465.00
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. Full year organic revenue increased 1% (2% reported) to $1.2 billion.GAAP earnings per share (EPS) was $0.25 versus $0.47 one year ago. Delivered adjusted EPS of $0.49 compared to $0.55 one year ago. Full year GAAP EPS was $1.05 versus $1.76 one year ago. Full year adjusted EPS was $1.77 versus $1.99 one year ago.Strong commercial execution in Diagnostics & Genomics led to 9% organic segment growth (15% reported) in the fo
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific d
MINNEAPOLIS, July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT to review fourth quarter and fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 7, 2024 Dial-in: 1-800-343-4136 or 1-203-518-9843 (for international callers) Conference ID: BioTechne Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested
MINNEAPOLIS, May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024. The quarterly dividend will be payable May 24, 2024, to all common shareholders of record on May 13, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseas
MINNEAPOLIS, May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights Third quarter organic revenue increased by 2% (3% reported) to $303.4 million.GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago.Strong commercial execution in Diagnostics & Genomics led to 10% organic segment growth (16% reported).Continued uptake of our cell and gene therapy workflow solutions, including record sales for our GMP reagent portfolio.Cash flow generated from operations increased to $223.5 million, a 31% increas
MINNEAPOLIS, April 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 1, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13745802 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Confere
MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2023. Second Quarter FY2024 Highlights Second quarter organic revenue declined by 2% (0% reported) to $272.6 million. Organic revenue remained flat (2% reported) in the first half of fiscal 2024 at $549.5 million.GAAP earnings per share (EPS) was $0.17 versus $0.31 one year ago. Adjusted EPS of $0.40 compared to $0.47 one year ago.The impact of the BioPharma macroeconomic conditions that the industry has experienced throughout the past calendar year increased in our fiscal second quarter. The company has been able to partially offset th
MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable February 26, 2024, to all common shareholders of record on February 12, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s
MINNEAPOLIS, Jan. 16, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Thursday, February 1, 2024, at 8:00 a.m. CST to review second quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 1, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13743935 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referenci
MINNEAPOLIS, Oct. 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Tuesday, October 31, 2023, at 8:00 a.m. CDT to review first quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 31, 2023 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference ID: 13741775 Webcast: https://investors.bio-technecom/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing
4 analysts have shared their evaluations of Bio-Techne (NASDAQ:TECH) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.75, with a high estimate of $95.00 and a low estimate of $81.00. This current average ref
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and announces $85 price target.
Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two patents owned by Advanced Cell Diagnostics, Inc. ((a Bio-Techne group company, NASDAQ:TECH) both be revoked; (2) that Advanced Cell Diagnostics' infringement claims against Molecular Instruments are dismissed; and (3) that Advanced Cell Diagnostics make a costs payment of £1.35 million (approximately $1.72 million at the current exchange rate) to Molecular Instruments.In a 2022 lawsuit filed at the High Court of England and Wales (proceedings no. HP-2022-000026), Advanced Cell Diagnostics alleged that Molecular Instruments' HCR™ RNA-ISH technology infringed European P
These large-cap stocks were the best performers in the last week amid earnings season. Are they in your portfolio? Carvana Co. (NYSE:CVNA) shares escalated 39.1% after it reported Q1 revenue of $3.061 billion, which beat the consensus estimate of $2.673 billion. Several analysts raised their forecasts. NIO Inc. (NYSE:NIO) shares jumped 21.5% after the company's April vehicle deliveries increased 134.6% year-over-year. Paramount Global (NASDAQ:PARAA) shares surged 21.5% after it reported first-quarter revenue of $7.685 billion, which missed the consensus estimate of $7.732 billion. The company said CEO Bob Bakish is stepping down from the studio. Paramount reportedly got a $26 billi
Benchmark analyst Robert Wasserman reiterates Bio-Techne (NASDAQ:TECH) with a Buy and maintains $95 price target.
Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target from $73 to $81.
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue guidance for the second quarter. AMD guided to second-quarter revenue of $5.7 billion plus or minus $300 million and a non-GAAP gross margin of about 53% against Street estimates of $5.7 billion in second-quarter revenue. Street expectations for fiscal year 2024 are for earnings of $3.40 per share and revenue of $24.13 billion, respectively, according to data from Benzinga Pro. Advanced Micro Devices shares dipped 6.9% to $147.44 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers CytomX Th
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday. Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results. Powell Industries posted GAAP earnings of $2.75 per share, beating market estimates of $1.77 per share. The company's quarterly sales came in at $255.108 million versus expectations of $201.447 million, according to data from Benzinga Pro. Powell Industries shares jumped 23.2% to $176.16 on Wednesday. Here are some other big stocks recording gains in today's session. Rocky Brands, Inc. (NASDAQ:RCKY) shares jumped 31.6% to $3
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
DEFA14A - BIO-TECHNE Corp (0000842023) (Filer)
DEF 14A - BIO-TECHNE Corp (0000842023) (Filer)
10-K - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
SD - BIO-TECHNE Corp (0000842023) (Filer)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023. Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years. Brenda has been and will continue to provide transition support until her March 3, 2023, retirement and will serve in a consulting capacity for special projects going forward. Mr. Bohnen has over 20 years of experience as a senior legal advisor, including serving as Bio-Techne's Associate General Counsel since 2019. During his tenure at Bio-T
MINNEAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Bio-Teche Corporation (NASDAQ:TECH) today announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's Chief Executive Officer (CEO) effective June 30, 2024. The Company's Board of Directors has begun its search for Mr. Kummeth's replacement, evaluating both internal and external candidates to assume the CEO position upon Kummeth's retirement at the end of its fiscal 2024. It is anticipated that Mr. Kummeth will continue to serve on Bio-Techne's Board of Directors upon his retirement. Mr. Kummeth has served as Chief Executive Officer and as a member of the Company's Board of Directors since April 2013. Under Mr. Kummeth's l
MINNEAPOLIS, Dec. 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Brenda Everson as Senior Vice President, Human Resources effective January 10, 2022. Ms. Everson succeeds Struan Robertson, who will be retiring from the Company. Mr. Robertson will remain with Bio-Techne through February 11, 2022, to ensure a smooth transition. Ms. Everson has over two decades of experience as a senior human resources leader across the technology and retail industries, most recently serving as Vice President, Human Resources for Midco, a leading internet and telecommunications provider. Previously Ms. Everson spent 18 years at Apple, Inc. in positions of increa
MINNEAPOLIS, Dec. 21, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3, 2022. Mr. Geist succeeds N. David Eansor, who will be retiring from the Company. Mr. Eansor will remain with Bio-Techne through the end of February 2022 to ensure a smooth transition. Mr. Geist has over two decades of experience as a senior life science tools leader, most recently serving as Chief Operating Officer for Quanterix, where he was responsible for enterprise-wide operations and strategy deployment. Previously Mr. Geist was Vice President & General Manager for two of Thermo Fisher Scientific's